RenovoRx(US:RNXT) Globenewswire·2025-12-01 13:30Core Viewpoint - RenovoRx, Inc. is actively commercializing its innovative targeted oncology therapies, particularly focusing on the RenovoCath device, which has shown growing clinical demand and market traction [1][2][6] Group 1: Company Updates - CEO Shaun Bagai will present at the iAccess Alpha Virtual Best Ideas Winter Investment Conference on December 9, 2025, to discuss the company's commercial efforts and market traction [1][4] - Year-to-date revenue for RenovoRx reached approximately $900,000 by the end of September 30, 2025, indicating progress in its commercialization efforts [2][7] - The company has received its first commercial purchase orders for RenovoCath devices and has seen repeat orders from several customers, including high-volume National Cancer Institute-designated centers [7] Group 2: Clinical Research and Development - The ongoing Phase III TIGeR-PaC clinical trial is evaluating intra-arterial gemcitabine delivered via RenovoCath in patients with locally advanced pancreatic cancer [3][8] - RenovoRx is also conducting a post-marketing registry study to capture real-world data on the safety and effectiveness of RenovoCath in patients with solid tumors [3] - The company supports investigator-initiated trials in borderline resectable and oligometastatic pancreatic cancer, which may broaden the application of its TAMP™ therapy platform [3][6] Group 3: Product Information - RenovoCath is an FDA-cleared drug-delivery device designed for targeted therapeutic delivery, aiming to minimize toxicities compared to systemic intravenous therapy [5][6] - The device is indicated for temporary vessel occlusion and the delivery of fluids, including therapeutic agents, to specific sites in the peripheral vascular system [5][9] - RenovoCath with gemcitabine has received Orphan Drug Designation for pancreatic cancer and bile duct cancer, providing seven years of market exclusivity upon FDA approval [10]